Fortress Biotech, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Fortress Biotech, Inc. (FBIO) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $1.68 per share for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2025-03-31
- Fortress Biotech, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $1.68.
- Fortress Biotech, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2022-03-31 was $2.50.
- Fortress Biotech, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2016-03-31 was $0.00.
- Fortress Biotech, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2015-03-31 was $0.00.
- Fortress Biotech, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $1.68.
- Fortress Biotech, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $0.54.
- Fortress Biotech, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2019 was $1.18.
- Fortress Biotech, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2015 was $0.00.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2024-12-31 | $1.68 10-K · filed 2025-03-31 | |||
| 2024-09-30 | $1.68 10-Q · filed 2024-11-14 | |||
| 2024-06-30 | $1.68 10-Q · filed 2024-08-13 | |||
| 2024-03-31 | $1.68 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | $0.54 10-K · filed 2023-03-31 | |||
| 2022-09-30 | $2.50 10-Q · filed 2022-11-14 | |||
| 2022-06-30 | $2.50 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | $2.50 10-Q · filed 2022-05-12 | |||
| 2019-12-31 | $1.18 10-K/A · filed 2021-04-09 | |||
| 2016-09-30 | $0.00 10-Q · filed 2016-11-09 | |||
| 2016-06-30 | $0.00 10-Q · filed 2016-08-09 | |||
| 2016-03-31 | $0.00 10-Q · filed 2016-05-10 | |||
| 2015-12-31 | $0.00 10-K · filed 2016-03-15 | |||
| 2015-09-30 | $0.00 10-Q · filed 2015-11-09 | |||
| 2015-06-30 | $0.00 10-Q · filed 2015-08-10 | |||
| 2015-03-31 | $0.00 10-Q · filed 2015-05-11 | |||
| 2014-12-31 | $0.00 10-K · filed 2015-03-16 | |||
| 2014-09-30 | $0.00 10-Q · filed 2014-11-06 | |||
| 2014-06-30 | $0.00 10-Q · filed 2014-08-11 | |||
| 2014-03-31 | $0.00 10-Q · filed 2014-05-12 | |||
| 2013-12-31 | $5.34 10-K · filed 2014-03-14 | |||
| 2013-09-30 | $6.07 10-Q · filed 2013-11-01 | |||
| 2013-06-30 | $6.07 10-Q · filed 2013-08-05 | |||
| 2013-03-31 | $5.66 10-Q · filed 2013-05-09 | |||
| 2012-12-31 | $6.52 10-K · filed 2013-03-18 | |||
| 2012-09-30 | $6.86 10-Q · filed 2012-11-14 | |||
| 2012-06-30 | $6.98 10-Q · filed 2012-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |